Shilpa Medicare Inks Nivolumab Biosimilar Co-Development Deal with Finland's Orion

Shilpa Medicare's subsidiary signed a co-development and supply agreement with Orion Corporation for a nivolumab biosimilar targeting Europe's $4.1B immuno-oncology market. Shilpa will manufacture and supply; Orion will commercialize exclusively.